Phenomenex and USP Offer Workshop on Practical Application of Chapter <621>
News Feb 15, 2010
Phenomenex Inc., a global leader in the manufacture of separation science consumables, announces that it will be teaching a half-day course in conjunction with USP (U.S. Pharmacopeia) Professional Education on the practical application of Chapter <621> to improve HPLC method stability and speed. The course will be offered each day of Pittcon in Room SR-49 at the Orange County Convention Center in Orlando. The fee of $395 ($495 after February 19) includes conferee registration to Pittcon, course materials and refreshments. Course dates and times are:
Monday, March 1 1:00 – 5:00 p.m.
Tuesday, March 2 8:30 – 12:30 p.m.
Wednesday, March 3 1:00 – 5:00 p.m.
Thursday, March 4 8:30 – 12:30 p.m.
USP Chapter <621> defines the adjustments that labs may make to their LC methods without having to revalidate. The course, taught by top technical managers from Phenomenex and senior USP scientists, will use a combination of lecture and small group exercises to teach ways to adjust HPLC methods in various situations while adhering to the Chapter <621> guidelines. The course will be valuable for lab mangers, bench chemists and QA/AC analysts who work with USP monographs for pharmaceuticals and nutraceuticals. Participants may register online at http://www.usp.org/goto/usp621.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE